Form 4: Veracyte Executive John Leite Reports Stock Transactions

Chief Commercial Officer John Leite reports acquisition of restricted stock units and subsequent sale of common stock under a 10b5-1 plan.

Summary

• John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., reported transactions involving the company's common stock.
• On March 6, 2025, Leite acquired 36,240 shares of common stock through restricted stock units.
• These restricted stock units vest 25% on March 2, 2026, and then 1/16 per quarter thereafter, contingent upon continued employment.
• On March 7, 2025, Leite sold 2,400 shares at a weighted average price of $31.035 and 5,011 shares at a weighted average price of $31.9588.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 6, 2024.
• Following these transactions, Leite directly owns 100,249 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. The use of a 10b5-1 plan suggests a planned and orderly approach to selling shares.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 plans to sell shares regularly to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sales could exert downward pressure on the stock price, but the impact is likely to be minimal due to the pre-planned nature of the transactions.

Key Dates